Osaera (Amikacin Sulfate)

Amikacin is used to treat serious infections caused by susceptible Gram‑negative bacteria.

• Severe sepsis: eradicates causative Gram‑negative pathogens and supports hemodynamic recovery.
• Hospital‑acquired pneumonia: provides bactericidal activity against resistant organisms.
• Complicated urinary tract infections: eliminates pathogens resistant to other antibiotics.
• Intra‑abdominal infections: targets mixed aerobic and anaerobic Gram‑negative flora.

• Amikacin binds to the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis. This results in rapid bactericidal activity against aerobic Gram‑negative organisms, including Pseudomonas aeruginosa and Enterobacteriaceae. Its high affinity for ribosomal RNA reduces the likelihood of resistance compared with other aminoglycosides.

Amikacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nephrotoxicity: dose‑related decline in renal function.
• Ototoxicity: reversible vestibular disturbances.
• Rash: mild skin eruptions.
• Fever: transient temperature elevation.

Serious or Rare Side Effects

• Permanent hearing loss: irreversible auditory damage.
• Severe renal failure: acute kidney injury requiring dialysis.
• Anaphylaxis: life‑threatening allergic reaction.
• Neuromuscular blockade: respiratory muscle weakness.

When using amikacin, clinicians should observe several safety precautions.

• Renal monitoring: assess serum creatinine and urine output regularly.
• Auditory monitoring: perform baseline and periodic hearing tests.
• Dose adjustment: reduce dosage in patients with impaired renal function.
• Avoid in myasthenia gravis: risk of exacerbating muscle weakness.
• Concurrent nephrotoxic drugs: limit use with vancomycin, cisplatin, or loop diuretics.
• Pregnancy and lactation: use only if benefits outweigh potential risks.
• Store below 25°C: keep in original packaging, protect from moisture and light.

Amikacin interacts with several medicines, requiring careful management.

Major Interactions (Avoid)

• Other nephrotoxic agents (e.g., vancomycin, cisplatin): increase risk of kidney damage.
• Other ototoxic agents (e.g., loop diuretics, gentamicin): amplify hearing loss.
• Neuromuscular blocking drugs (e.g., succinylcholine, pancuronium): potentiate respiratory paralysis.
• Concurrent use with high-dose penicillins: may reduce antibacterial efficacy.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may modestly affect renal clearance.
• ACE inhibitors or ARBs: monitor renal function and potassium levels.
• Diuretics (e.g., furosemide): watch for additive nephrotoxicity.
• Proton pump inhibitors: observe for potential changes in drug absorption.